Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ADI-PEG 20 + Ifosfamide + Mesna |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADI-PEG 20 | Pegargiminase|ADI-PEG20|pegylated arginine deiminase | Pegargiminase (ADI-PEG 20) is polyethylene glycol-conjugated arginine deiminase which degrades arginine, thereby depleting arginine and potentially inhibiting growth of arginine-dependent tumor cells (PMID: 22864522, PMID: 30796035, PMID: 32409304). | ||
Ifosfamide | Cyfos | Z4942 | Chemotherapy - Alkylating 18 | Cyfos (ifosfamide) is an alkylating agent, which cross-links DNA, thereby inhibiting DNA replication (NCI Drug Dictionary). |
Mesna | Mesnex | D-7093|UCB 398|MSA|mercaptoethane sulfonate|Mesnum |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05813327 | Phase Ib/II | ADI-PEG 20 + Ifosfamide + Mesna | Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma | Recruiting | USA | 0 |